Category: pharmacological
Aliases: Tradjenta, Trajenta, BI-1356
Highly selective, tight-binding DPP-4 inhibitor — prevents inactivation of endogenous GLP-1 and GIP → enhanced glucose-dependent insulin release and suppressed glucagon. Unique among DPP-4 inhibitors in being eliminated primarily unchanged via bile/feces (<5% renal) with a non-linear PK driven by saturable DPP-4 target binding — effective t½ ~12 h despite terminal t½ of 100+ h due to target-mediated disposition.
PO: 12h